NASDAQ · LXRX

Lexicon Pharmaceuticals, Inc.

$2.29 -$0.01 (-0.43%) 1D After hours

Key Metrics

$1.02B
Market cap
P/E · TTM
$69.64M
Revenue · TTM
−$26.09M
Net income
EPS · TTM $-0.07
Dividend yield
Free cash flow
Beta · 1Y 1.40
EBITDA · TTM −$23.67M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 8
    The stock moved +19.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8
  • Jan 30
    The stock moved -19.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jan 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.02B
Enterprise value$900.68M
Shares outstanding444.2M
52-wk range$1.00 – $2.68
Avg volume · 20D3.1M
Net cash $120.97M
Book value / share$0.56
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Lexicon Pharmaceuticals, Inc.
IPO dateApr 7, 2000
Employees81

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S14.67
P/FCF
EV/EBITDA
EV/Sales12.93
Graham №

Profitability

Gross
Operating -34.8%
Net -37.5%
FCF
ROE / ROIC -15.0% · —

Financial Health

Current ratio18.79
Quick ratio18.77
Debt / equity0.24
Debt / EBITDA -2.10
Net cash $120.97M
Working capital$176.13M

Cash Flow · TTM

Operating CF −$38.80M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings